Open an account

Evelo Biosciences

EVLO · OTC

$0.0002−$0.0002 (−50.00%)TodayMarket closed ·
No price history for this range.

About EVLO

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. The company is headquartered in Foxboro, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2018-05-09. The firm is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.

Employees
66
Headquarters
FOXBORO, Massachusetts
Listed
May 9, 2018
Sector
Health Care
Industry
Biotechnology
Website
evelobio.com

EVLO key statistics

Market cap
3.80K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
8.40K
Volume
53
Open price
$0.0002
High today
$0.0002
Low today
$0.0002
52 Week high
$0.0005
52 Week low
$0.00

Evelo Biosciences (EVLO) at a glance

As of Oct 19, 2026, Evelo Biosciences (EVLO) shares are priced at $0.0002, giving the company a market cap of 3.80K and a price-to-earnings ratio of 0.00.

Volume so far is 53 shares, below the average of 8.40K shares a day.

Over the past year Evelo Biosciences has ranged from $0.00 to $0.0005, and now sits 40% of the way up that range.

Evelo Biosciences met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY23 it reported -$3.78 per share against an estimate of -$3.37.

EVLO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 14.4% on average.

  1. Q3 FY21: reported -$12.60 per share against an estimate of -$11.02
  2. Q4 FY21: reported -$10.80 per share against an estimate of -$12.44
  3. Q1 FY22: reported -$11.20 per share against an estimate of -$11.87
  4. Q2 FY22: reported -$8.00 per share against an estimate of -$8.84
  5. Q3 FY22: reported -$5.60 per share against an estimate of -$6.83
  6. Q4 FY22: reported -$4.20 per share against an estimate of -$5.63
  7. Q1 FY23: reported -$4.60 per share against an estimate of -$3.22
  8. Q2 FY23: reported -$3.78 per share against an estimate of -$3.37

EVLO news

  • Press releasePRNewswire

    Alltrna Announces Updates to Its Board of Directors

Similar companies

Companies in the same industry as Evelo Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.